MARKET

ACRS

ACRS

Aclaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.68
-0.35
-1.29%
After Hours: 26.85 +0.17 +0.64% 16:58 04/16 EDT
OPEN
27.36
PREV CLOSE
27.03
HIGH
27.37
LOW
25.73
VOLUME
495.46K
TURNOVER
--
52 WEEK HIGH
30.38
52 WEEK LOW
1.020
MARKET CAP
1.38B
P/E (TTM)
-22.1632
1D
5D
1M
3M
1Y
5Y
Alopecia Treatment Market Status and Forecast by Players, Regions to 2027
Apr 16, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Alopecia Treatment Market: Global Demand Analysis & Opportunity Outlook 2027"...
AmericaNewsHour · 1d ago
Global Tyrosine Protein Kinase JAK1 Market Outlook, Industry Analysis and Prospect 2021-2026
Heraldkeepers · 2d ago
Alopecia Market Key Companies, Business Opportunities, Competitive Landscape and Industry Analysis Research Report by 2027
Market Insight Reports · 3d ago
Topical Drug Delivery Market Business Opportunities, Demand, Insights Research And Outlook 2021 To 2027
Market Insight Reports · 5d ago
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8)
Benzinga · 04/09 11:26
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 04/08 12:14
COVID-19 Pandemic Effect and Impact Analysis on Seborrhea Drugs Market by 2027
Apr 08, 2021 (Market Insight Reports) -- The latest report as Seborrhea Drugs Market acknowledges Size, Application Segment, Type, Regional Outlook, Market...
Market Insight Reports · 04/08 10:24
Alopecia Market Analysis, Share, Merger, Acquisition, Size Estimation, New Investment Opportunities, Statistics, Global Industry Overview, and Forecast till 2027
Apr 07, 2021 (Market Insight Reports) -- Rising occurrences of alopecia and increasing incidence of chronic diseases are among the significant factors...
Market Insight Reports · 04/07 14:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRS. Analyze the recent business situations of Aclaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRS stock price target is 29.33 with a high estimate of 38.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 39.95M
% Owned: 77.12%
Shares Outstanding: 51.80M
TypeInstitutionsShares
Increased
15
2.73M
New
32
6.34M
Decreased
22
2.52M
Sold Out
6
111.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Neal Walker
Co-Founder/Chief Financial Officer
Frank Ruffo
Co-Founder/Chief Compliance Officer/Secretary
Kamil Ali-Jackson
Other
David Gordon
Director
Vincent Milano
Independent Director
Maxine Gowen
Independent Director
William Humphries
Independent Director
Anand Mehra
Independent Director
Christopher Molineaux
Independent Director
Andrew Powell
Independent Director
Bryan Reasons
Independent Director
Andrew Schiff
No Data
About ACRS
Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.